Kos: Aspirin reduces 'flushing' for patients taking cholesterol drug Niaspan

By Elaine Rigoli

Tampa, Fla., July 25 - Kos Pharmaceuticals, Inc. said the results from a study evaluating the benefits of aspirin in combination with a maximum dose of optimized Niaspan showed statistically significant reductions in the incidence and intensity of flushing, compared to placebo administration.

The trial was intended to study the incidence, duration and severity of flushing, a relatively common but transient effect for patients who take Niaspan to increase HDL-C, or "good" cholesterol.

In this flush-provocation study, subjects were administered 650 mg of aspirin either 30 minutes before or at the same time as a single dose of 2,000 mg of optimized Niaspan.

The company added that even though the study was designed to provoke flushing by administering a high dose to treatment-naive subjects, only about one-half of the subjects reported a flush with optimized Niaspan plus aspirin.

Kos is a specialty pharmaceutical company based in Cranbury, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.